Open AccessAssociation of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
Author(s) -
Wendy De Roock,
Derek J. Jonker,
Federica Di Nicolantonio,
Andrea SartoreBianchi,
Dongsheng Tu,
Salvatore Siena,
Simona Lamba,
Sabrina Arena,
Milo Frattini,
Hubert Piessevaux,
Eric Van Cutsem,
Chris O’Callaghan,
Shirin KhambataFord,
John Zalcberg,
John Simes,
Christos S. Karapetis,
Alberto Bardelli,
Sabine Tejpar
Publication year - 2010
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2010.1535
Subject(s) - cetuximab , kras , medicine , colorectal cancer , oncology , hazard ratio , cancer , confidence interval
Patients with metastatic colorectal cancer who have KRAS codon 12- or KRAS codon 13-mutated tumors are presently excluded from treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom